Burke Michael J, Walterhouse David O, Jacobsohn David A, Duerst Reggie E, Kletzel Morris
Division of Hematology, Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60614-3394, USA.
Pediatr Blood Cancer. 2007 Aug;49(2):196-8. doi: 10.1002/pbc.21182.
The role of tandem high-dose chemotherapy (HDC) with autologous peripheral hematopoietic progenitor cell rescue (APHPCR) in patients with Ewing Family Tumors (EFT) is controversial. We initiated treatment for eight consecutive patients with high-risk EFT with HDC and APHPCR from 1992 to 2003. There were no treatment related deaths. Four patients remain in complete remission, including three who did not undergo local therapy to bone at either the primary or metastatic sites. Our experience has shown that treatment of EFT patients with tandem HDC with APHPCR may benefit a subgroup of high-risk patients in whom optimal local therapy is not possible.
序贯大剂量化疗（HDC）联合自体外周造血祖细胞救援（APHPCR）在尤因家族肿瘤（EFT）患者中的作用存在争议。1992年至2003年，我们对8例连续的高危EFT患者采用HDC和APHPCR进行治疗。没有与治疗相关的死亡病例。4例患者仍处于完全缓解状态，其中3例在原发或转移部位均未接受骨局部治疗。我们的经验表明，对EFT患者采用序贯HDC联合APHPCR治疗可能使无法进行最佳局部治疗的高危患者亚组受益。
